Evaluation of Aryoseven Safety (Recombinant Activated Factor VII) in Patients with Bleeding Disorders (An Observational Post-Marketing Surveillance Study)
Background: Recombinant activated factor VII induces hemostasis in patients with coagulopathy disorders. AryoSeven™ as a safe Iranian Recombinant activated factor VII has been available on our market. This study was performed to establish the safety of AryoSeven on patients with coagulopathy disorde...
Saved in:
Main Authors: | Gholamreza Toogeh (Author), Hassan Abolghasemi (Author), Peyman Eshghi (Author), Mohammadreza Managhchi (Author), Mohammadreza Shaverdi-niasari (Author), Katayoon Karimi (Author), Samin Roostaei (Author), Neda Emran (Author), Alireza Abdollahi (Author) |
---|---|
Format: | Book |
Published: |
Iranian Society of Pathology,
2016-07-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Use of Low-Dose Recombinant Factor Ⅶa for Uncontrolled Perioperative Bleeding
by: Zhi-gang Chang MD, PhD, et al.
Published: (2020) -
Evidence supporting the use of recombinant activated factor VII in congenital bleeding disorders
by: Pär I Johansson, et al.
Published: (2010) -
Comparative evaluation of the safety and efficacy of recombinant FVIII in severe hemophilia A patients
by: Hassan Abolghasemi, MD, et al.
Published: (2018) -
The Longevity of Band and Loop and Pontic-Crown Fixed Space Maintainers in Children Aged 4 to 7 Years: A Randomized Controlled Trial
by: Alireza Eshghi, et al.
Published: (2018) -
Optimal use of recombinant factor VIIa in the control of bleeding episodes in hemophilic patients
by: John Puetz
Published: (2010)